Online inquiry

IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15610MR)

This product GTTS-WQ15610MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLC29A2 gene. The antibody can be applied in Glycogen storage disease type II (GSD-II) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15610MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ61MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ15493MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ987MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ4408MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ9167MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ11436MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ7553MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ12619MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMNITARG™
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW